Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Stojanov, S; Dejaco, C; Lohse, P; Huss, K; Duftner, C; Belohradsky, BH; Herold, M; Schirmer, M.
Clinical and functional characterisation of a novel TNFRSF1A c.605T>A/V173D cleavage site mutation associated with tumour necrosis factor receptor-associated periodic fever syndrome (TRAPS), cardiovascular complications and excellent response to etanercept treatment.
Ann Rheum Dis. 2008; 67(9): 1292-1298.
Doi: 10.1136/ard.2007.079376
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Führende Autor*innen der Med Uni Graz
- Dejaco Christian
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- To study the clinical outcome, treatment response, T-cell subsets and functional consequences of a novel tumour necrosis factor (TNF) receptor type 1 (TNFRSF1A) mutation affecting the receptor cleavage site. Patients with symptoms suggestive of tumour necrosis factor receptor-associated periodic syndrome (TRAPS) and 22 healthy controls (HC) were screened for mutations in the TNFRSF1A gene. Soluble TNFRSF1A and inflammatory cytokines were measured by ELISAs. TNFRSF1A shedding was examined by stimulation of peripheral blood mononuclear cells (PBMCs) with phorbol 12-myristate 13-acetate followed by flow cytometric analysis (FACS). Apoptosis of PBMCs was studied by stimulation with TNFalpha in the presence of cycloheximide and annexin V staining. T cell phenotypes were monitored by FACS. TNFRSF1A sequencing disclosed a novel V173D/p.Val202Asp substitution encoded by exon 6 in one family, the c.194-14G>A splice variant in another and the R92Q/p.Arg121Gln substitution in two families. Cardiovascular complications (lethal heart attack and peripheral arterial thrombosis) developed in two V173D patients. Subsequent etanercept treatment of the V173D carriers was highly effective over an 18-month follow-up period. Serum TNFRSF1A levels did not differ between TRAPS patients and HC, while TNFRSF1A cleavage from monocytes was significantly reduced in V173D and R92Q patients. TNFalpha-induced apoptosis of PBMCs and T-cell senescence were comparable between V173D patients and HC. The TNFRSF1A V173D cleavage site mutation may be associated with an increased risk for cardiovascular complications and shows a strong response to etanercept. T-cell senescence does not seem to have a pathogenetic role in affected patients.
- Find related publications in this database (using NLM MeSH Indexing)
- Adolescent -
- Adult -
- Amino Acid Sequence -
- Anti-Inflammatory Agents, Non-Steroidal - therapeutic use
- Apoptosis - immunology
- Base Sequence -
- CD4-Positive T-Lymphocytes - immunology
- CD8-Positive T-Lymphocytes - immunology
- Cardiovascular Diseases - genetics Cardiovascular Diseases - immunology
- Cell Aging - immunology
- Cells, Cultured -
- DNA Mutational Analysis - methods
- Familial Mediterranean Fever - complications Familial Mediterranean Fever - drug therapy Familial Mediterranean Fever - genetics Familial Mediterranean Fever - immunology
- Female -
- Humans -
- Immunoglobulin G - therapeutic use
- Male -
- Middle Aged -
- Molecular Sequence Data -
- Monocytes - immunology
- Mutation -
- Pedigree -
- Receptors, Tumor Necrosis Factor - therapeutic use
- Receptors, Tumor Necrosis Factor, Type I - blood Receptors, Tumor Necrosis Factor, Type I - genetics
- Receptors, Tumor Necrosis Factor, Type II - blood
- T-Lymphocyte Subsets - immunology
- Treatment Outcome -
- Tumor Necrosis Factor-alpha - antagonists and inhibitors Tumor Necrosis Factor-alpha - immunology